Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Iberdomide→

Iberdomide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1323403-33-3
Molecular formula
C25H27N3O5
Molecular weight
449.507 g/mol
Drug class
Cereblon E3 ligase modulator (CELMoD)immunomodulatory antineoplastic small molecule
Mechanism of action
Binds cereblon, the substrate receptor of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and degradation of transcription factors including Ikaros (IKZF1) and Aiolos (IKZF3). This alters myeloma-cell survival and immune-cell function.
Indications / reported uses
  • In combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent under the US FDA ZENBEXUS indication (approved 13 August 2026)

Sources: US FDA — Novel Drug Approvals 2026 (ZENBEXUS/iberdomide) · FDA Orphan Drug database — Iberdomide · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Cereblon E3 ligase modulator (CELMoD); immunomodulatory antineoplastic small molecule

Mechanism of action

Binds cereblon, the substrate receptor of the CRL4 E3 ubiquitin ligase complex, promoting ubiquitination and degradation of transcription factors including Ikaros (IKZF1) and Aiolos (IKZF3). This alters myeloma-cell survival and immune-cell function.

General use cases

  • In combination with daratumumab and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent under the US FDA ZENBEXUS indication (approved 13 August 2026)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Iberdomide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Iberdomide Permitted Daily Exposure (PDE) report (the Iberdomide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Iberdomide Occupational Exposure Limit (OEL) report (the Iberdomide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.